{1 (3 ML cabotegravir 200 MG/ML Injection) / 1 (3 ML rilpivirine 300 MG/ML Injection) } Pa... — RxCUI 2475415
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Rilpivirine: what it is, how it’s used, side effects, and interactions.
- Rilpivirine is one piece of your HIV treatment — it blocks a specific enzyme the virus uses to copy itself. But HIV is smart and can develop resistance if only one medicine is used...
- What exactly is rilpivirine and why do I have to take it with other HIV medicines?
- It really does matter. When rilpivirine is taken without food, your body absorbs about 40% less of the medicine — and if levels in your blood fall too low, the virus can start repl...
- Why is it so important to take this with food? Can't I just take it whenever?
🕸️ Concept Web — How {1 (3 ML cabotegravir 200 MG/ML Injection) / 1 (... Connects
RxCUI 2475415 Generic pack · GPCK
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 2
The active substance itself — no strength, form, or brand attached yet.
-
Cabotegravir
2475077IN -
Rilpivirine
1102270IN
-
Cabotegravir
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Apretude
2588044BN
-
Apretude
-
Dose forms 8
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Cabotegravir Injection
2588076SCDF -
Rilpivirine Injection
2594979SCDF -
Cabotegravir Injectable Product
2475408SCDG -
Rilpivirine Injectable Product
2475412SCDG -
Cabotegravir Injection [Apretude]
2588079SBDF -
Apretude Injectable Product
2588046SBDG -
Pack
746839DF -
Injectable Product
1151126DFG
-
Cabotegravir Injection
-
Clinical & branded drugs 6
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
3 ML cabotegravir 200 MG/ML Injection
2588077SCD -
3 ML rilpivirine 300 MG/ML Injection
2594980SCD -
Cabotegravir 200 MG/ML
2475407SCDC -
Rilpivirine 300 MG/ML
2475411SCDC -
3 ML cabotegravir 200 MG/ML Injection [Apretude]
2588080SBD -
Cabotegravir 200 MG/ML [Apretude]
2588045SBDC
-
3 ML cabotegravir 200 MG/ML Injection
-
Packs 1
Fixed collections of drugs packaged and sold together, like dose packs.
🔀 Generic ⇄ Brand Crosswalk
Generic (Clinical) Concepts
-
3 ML cabotegravir 200 MG/ML Injection
SCD · 2588077 -
3 ML rilpivirine 300 MG/ML Injection
SCD · 2594980 -
Cabotegravir 200 MG/ML
SCDC · 2475407 -
Rilpivirine 300 MG/ML
SCDC · 2475411 -
Cabotegravir Injection
SCDF · 2588076 -
Rilpivirine Injection
SCDF · 2594979 -
Cabotegravir Injectable Product
SCDG · 2475408 -
Rilpivirine Injectable Product
SCDG · 2475412
Brand-Name Concepts
-
3 ML cabotegravir 200 MG/ML Injection [Apretude]
SBD · 2588080 -
{1 (3 ML cabotegravir 200 MG/ML Injection) / 1 (3 ML rilpivirine 300 MG/ML Injection) } Pack [CABENUVA 600 MG / 900 MG]
BPCK · 2475416 -
Cabotegravir 200 MG/ML [Apretude]
SBDC · 2588045 -
Cabotegravir Injection [Apretude]
SBDF · 2588079 -
Apretude Injectable Product
SBDG · 2588046 -
Apretude
BN · 2588044
📦 FDA Products & Package NDCs
3 products · 3 package NDCs
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 49702-0240-15 | 1 KIT in 1 CARTON (49702-240-15) * 3 mL in 1 VIAL (49702-2... | Cabenuva | ViiV Healthcare Company | 2021-01-21 |
| 49702-0253-15 | 1 KIT in 1 CARTON (49702-253-15) * 2 mL in 1 VIAL (49702-2... | Cabenuva | ViiV Healthcare Company | 2021-01-21 |
| 49702-0266-63 | 1 KIT in 1 CARTON (49702-266-63) * 3 mL in 1 VIAL (49702-2... | Cabenuva | ViiV Healthcare Company | 2025-01-21 |
🧾 Billing Codes (HCPCS)
| Code | Descriptor | Mapped packages | Sources |
|---|---|---|---|
| J0741 | Inj, cabote rilpivir 2mg 3mg | 2 | CMS |
🗃️ Sources & Limits
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.